Phase 1 Psoriasis Trial, Recruiting NCT07024602 Sponsor: Ascletis Pharma (China) Co., Limited Condition: Psoriasis
Back to Psoriasis

Phase 1 Psoriasis Trial, Recruiting

NCT07024602
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old (inclusive) at the time of your screening appointment
  • You are willing and able to give your informed consent before any study procedures take place
  • You have veins that can be accessed easily enough to allow blood samples to be taken

Who may not be able to join:

  • You are a woman who is currently pregnant, breastfeeding, or planning to become pregnant during the study or within 3 months after the last dose of the study treatment
  • You have a current or past medical or mental health condition that the study doctor believes could affect your safety or put you at unnecessary risk during the study
  • You have taken certain medications that suppress the immune system (such as methotrexate, apremilast, azathioprine, cyclosporine, or several others) within the 4 weeks before your first dose of the study treatment (confirm with trial site)
  • You have any other condition that, in the opinion of the study doctor or the study sponsor, means it would not be appropriate for you to take part or that might affect your ability to complete the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 18986192094

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Ascletis Pharma (China) Co., Limited
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Adverse Events; Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov